Chick-fil-A has made a significant announcement, indicating a shift in its approach regarding the use of certain antibiotics in its chicken products. This decision marks a departure from a commitment the company previously made back in 2014.
In a recent statement shared on its official website, Chick-fil-A outlined its plan to implement this change starting in the spring of 2024.
The company stated that the adjustment aims to ensure the continuous provision of high-quality chicken, aligning with the expectations of its customers.
Highlighting the specifics of this adjustment, the statement clarified that the antibiotics permitted will not pose risks to human health.
They will only be administered if deemed necessary for the well-being of the animal and its immediate surroundings.
Chick-fil-A elaborated on the rationale behind this policy shift. The company cited anticipated difficulties in sourcing chicken supplies that meet its stringent quality standards as a primary factor influencing this decision.
This move by Chick-fil-A is part of a broader trend, mirroring similar adjustments made by other companies in the industry.
Tyson Foods, a prominent supplier of chicken, made headlines last summer by reversing its stance on antibiotic use in its chicken supply chain. This decision came after the company had transitioned to antibiotic-free practices in 2017.
Similarly, Panera Bread, known for its early embrace of antibiotic-free commitments, recently adjusted its animal welfare policies.
According to a Reuters report from earlier this month, Panera Bread now permits the use of antibiotics in its pork and turkey products, among other alterations.
Internal documents from Panera indicated that its previous no-antibiotics policy severely restricted its supply chain options, limiting access to only 5% of the available pork in the market.
